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Abstract
Plasmacytoid dendritic cells (pDC) are the major producers of type I interferons (IFNs) in humans and rapidly produce IFN-
a in response to virus exposure. Although HIV infection is associated with pDC activation, it is unclear why the innate
immune response is unable to effectively control viral replication. We systematically compared the effect of HIV, Influenza,
Sendai, and HSV-2 at similar target cell multiplicity of infection (M.O.I.) on human pDC function. We found that Influenza,
Sendai, HSV-2 and imiquimod are able to rapidly induce IFN-a production within 4 hours to maximal levels, whereas HIV had
a delayed induction that was maximal only after 24 hours. In addition, maximal IFN-a induction by HIV was at least 10 fold
less than that of the other viruses in the panel. HIV also induced less TNF-a and MIP-1b but similar levels of IP-10 compared
to other viruses, which was also mirrored by delayed upregulation of pDC activation markers CD83 and CD86. BDCA-2 has
been identified as an inhibitory receptor on pDC, signaling through a pathway that involves SYK phosphorylation. We find
that compared to Influenza, HIV induces the activation of the SYK pathway. Thus, HIV delays pDC IFN-a production and pDC
activation via SYK phosphorylation, allowing establishment of viral populations.
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Introduction
The innate immune system is essential for the initial detection of
invading viruses and subsequent activation of adaptive immunity.
The type 1 interferons (IFNs) are the central effector cytokine of
innate immunity and have been shown to inhibit HIV-1 (HIV)
replication in vitro [1,2,3]. Plasmacytoid dendritic cells (pDC) are
the major producers of type I IFNs in mice and humans. PDCs
predominantly utilize TLRs for virus detection and IFN-a pro-
duction [4], activation occurring through TLRs 7 and 9. Both of
these receptors are endosomal and are triggered by ssRNA or
double stranded CpG-DNA, respectively [5]. The IFN response
by pDCs is both rapid and robust. With over 50% of the induced
RNA transcripts following TLR7 and TLR9 triggering encoding
for type I IFN, the result is production of 3–10 pg/cell of IFN-
a protein at 24 h, 100-1000X more than any other cell type in the
blood [6]. The enhanced capacity for pDCs to produce IFN is
related to the high constitutive expression of IRF7 in pDCs, which
allows for these cells to bypass the classic autocrine feedback
involving IFN-beta (IFN-b) [7,8].
Pathways downstream of TLR 7/9 signaling in pDCs
bifurcates, leading to IFN-a production as well as maturation
and inflammatory cytokine production [9,10]. The pathway
leading to IFN-a production depends on IRF7 phosphorylation
and ubiquitination, following which IRF7 dimerizes, migrates to
the nucleus, and facilitates transcription of IFN-a and IFN-b genes
[9,11,12]. Maturation involves TNF Receptor Associated Factor
(TRAF) 6 and the Interleukin-1 receptor-associated kinase (IRAK)
4, which mediates the downstream activation of NF-kB and
MAPKs [10,13]. NF-kB and MAPK activation result in pDC
maturation, manifested by CD83, co-stimulatory molecule ex-
pression, and pro-inflammatory cytokine production, which in-
clude MIP-1a, IP-10, TNF-a, IL-6, IL-8, IL-10 and IL-12
[14,15,16,17]. PDC maturation favors the priming of adaptive
immunity resulting in T cell activation and inflammation [5,6,18].
Thus pDCs, through a dual signaling pathway, link innate
immune responses to adaptive immune responses.
HIV has been shown to activate pDC directly, causing them to
mature and produce IFN-a and TNF-a [18]. PDC activation via
HIV has been shown to require interactions between CD4 on
pDCs and HIV gp120, as well as internalization and interaction
between HIV-RNA and TLR 7 [19]. In SIV infection, pDC are
observed 1 day post-infection at the vaginal mucosa near sites of
replicating virus, but are unable to control subsequent viral
replication and dissemination [20]. These pDC were also shown to
express the chemokines MIP-1a, MIP-1b, and MIP-3a, which
could play a role in recruiting more pDC and activated CD4 T
cells to be targeted for infection. It is currently unclear what role
pDCs are playing during the early events following viral exposure.
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utilized high titers of virus, likely exceeding levels found in vivo
[19,21,22]. As such, it is unclear whether pDC can actually
undergo normal activation in response to doses of virus expected
in the setting of sexual transmission. In addition, the kinetics of
IFN-a production to HIV has not been previously studied, nor
have there been detailed comparisons of pDC responses to other
RNA viruses that do not cause chronic infections [19,22]. HIV is
a rapidly replicating RNA virus [23], with viral production rates of
up to 5610
4 viruses/infected cell, a virus doubling time of 0.65
days and a mean basic reproductive ratio of 8.0 [24,25]. These
rapid replication kinetics could potentially overwhelm the in-
hibitory effects of type I IFNs if the pDC response is not
adequately rapid or robust. In order to address these aspects, we
compared the direct effect of HIV with a panel of common virus
pathogens, many of which have similar replication kinetics to HIV
[26].
Results
Influenza Virus Induces Greater IFN-a from pDC
Compared to HIV
We used a comparative approach to examine differences in
pDC responsiveness to HIV and other viruses. In order to
standardize for the effects of different viruses on human pDC, we
used similar multiplicities of infection (M.O.I.s) of viruses, where
the M.O.I. is calculated from the virus infections of their main
target cell. In the first set of experiments, PBMC from healthy
volunteers were co-cultured with HIVBAL, and compared to
Influenza (both at an M.O.I. of 0.1) for 8 hours and then analyzed
by flow cytometry for intracellular IFN-a production. PDCs were
selected by positive staining for BDCA-2 and CD123, and
negative staining for CD14 (Fig. 1A). A representative flow
cytometry experiment is shown in Fig. 1B, with summary data
from 3 individuals in Fig. 1C. We found that stimulation with
influenza virus for 8 hours induced a greater percentage of IFN-
a expressing pDC compared to HIV isolates at similar M.O.I.s.
We then isolated pure populations of pDC by negative depletion of
fresh PBMC from normal volunteers and co-cultured the pDC
(purity 80–95%) with HIVBAL, HIVNL-43, or influenza [A/PR/8/
34 (H1N1)] at an M.O.I. of 0.5 (for HIV, equivalent to 1.76 ng of
p24 antigen) and measured IFN-a production in culture superna-
tant after 8 hours by ELISA. Summary data from 4 individuals,
depicted in Fig. 1D further demonstrates that Influenza virus at
comparable infectious doses is able to induce greater amounts of
IFN-a in culture supernatants when compared to two strains of
HIV.
HIV Induces a Delayed IFN-a Response in pDC Compared
to Other Viruses
To compare the kinetics of IFN-a production from pDC after
exposure to HIV and a larger panel of viruses, freshly isolated
pDC from healthy volunteers were co-cultured with 0.5 M.O.I. of
herpes simplex virus (HSV)-2, HIVBAL, HIVNL43, Influenza
(H1N1), Sendai virus (18 HA units) and the TLR7 agonist
imiquimod (20 mg/ml), and supernatants were sampled for IFN-
a. Representative data from five individuals comparing HIV and
Influenza are shown in Fig. 2A and summary data from all viruses
from all individuals are shown in Fig. 2B. In addition, these
differences were observed through a range of M.O.I.s and a range
of RNA copy numbers of respective viruses (Fig. 3b and Table 1).
These experiments demonstrate that RNA viruses such as
Influenza, and Sendai induce IFN-a rapidly reaching about 90%
of their maximal production by 4 hours of stimulation, whereas for
HIV, maximum production of IFN-a was only achieved at 48
hours post virus exposure, at comparable RNA copy numbers. In
addition, HIV viruses induced significantly less IFN-a even at
maximal production when compared to Influenza, Sendai, HSV
or imiquimod stimulation at similar target cell M.O.I.s.
Figure 1. IFN-a production from pDCs following stimulation
with HIV or Influenza. (A) Gating strategy used to identify CD14
negative BDCA-2 positive CD123 positive pDCs. (B) PBMCs from HIV
negative individuals were treated with either Influenza (M.O.I=0.1) or
HIVBAL (M.O.I=0.1) in the presence of GolgiPlug
TM for 8 hours and
stained for intracellular IFN-a expression. Shown is a representative flow
cytometry plot. (C) Summary data of pDCs from 3 individuals measuring
intracellular IFN-a expression following stimulation with Influenza
(M.O.I=0.1) or HIVBAL (M.O.I=0.1) (D) Isolated pDCs from 3 HIV negative
patients were stimulated with Influenza (M.O.I=0.5) and HIVBAL
(M.O.I=0.5) for 8 hours, and levels of IFN-a in supernatant were
quantified by ELISA. Mean 6 SEM, *=p,0.05.
doi:10.1371/journal.pone.0037052.g001
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to Other Viruses
PDCs are capable of producing a range of cytokines and
chemokines that may be involved in directing adaptive immune
responses at the site of infection. As such, we used a cytometric
bead array assay to examine the levels of MIP-1b, IP-10, TNF-a,
IL-10 and IL-12 in pDC supernatants following stimulation with
the panel of viruses. Examination of cytokine production in
isolated pDC samples after virus exposure showed similarly
delayed kinetics for both HIV isolates tested (Fig. 4). Influenza,
Sendai, HSV and imiquimod induced MIP-1b, TNF-a and IP-10
with similar kinetics: MIP-1b appeared rapidly, particularly in
Figure 2. Kinetics of IFN-a production. Isolated pDCs from five HIV negative donors were rested overnight, and treated with a panel of stimuli as
described in the materials and methods. Levels of IFN-a in supernatants were quantified by CBA as part of a panel of other cytokines. (A) Quantified
IFN-a (pg/ml) present in culture supernatant of 3–5 donors (N1-N5) at various time points (represented by blue shaded bars) following stimulation by
HIVBAL, HIVNL43 or Influenza (B) Mean 6 SEM concentrations of IFN-a present in supernatants at various time points following stimulation by HIVBAL,
(red), HIVNL43 (orange), Influenza (yellow), HSV-1 (green), Imiquimod (light blue), Sendai virus (dark blue), and medium control (white) from data from
5 donors.
doi:10.1371/journal.pone.0037052.g002
HIV Delays pDC Responses
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37052Figure 3. Response of pDC to varying amounts of viruses. 2610
4 isolated pDCs were plated in 96 well flat bottom plates overnight in R10+IL-
3, then treated for designated time points with various concentrations of virus based on MOI or imiquimod (mg/ml) in a) and RNA copy numbers in b).
Supernatants were then harvested and analyzed by ELISA for IFN-a. Each experiment is representative of one of two donors, performed in duplicate.
doi:10.1371/journal.pone.0037052.g003
Table 1. Viruses used for RNA quantitation.
Infectious Particles Protein (p24, or HA)
Theoretical Viral
Particles RNA copies Nucleotides
HIVBAL 1.0610









Influenza A H1N1 1.0610




Standardized to an MOI of 0.5 on 20,000 pDCs.
*Based on 2000 p24 molecules/virus.
**Based on 400 HA molecules/virus.
doi:10.1371/journal.pone.0037052.t001
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a was detected at 12–24 hours post stimulation (Fig. 4C), and IP-
10 was seen relatively later at 24–48 hours (Fig. 4B). In contrast,
HIV tended not to induce comparable levels of cytokines over the
time period measured, with the exception of IP-10. Neither IL-10
nor IL-12 was detected from pDC in any of the treatments. Thus,
in comparison to other RNA viruses tested, HIV induced fewer
pro-inflammatory cytokines.
TLR signaling of pDC typically results in maturation of pDCs,
antigen presentation, and expression of activation markers such as
MHCII, CD83, CD80 and CD86 [19,27,28,29,30,31]. As such,
we tested whether HIV induced comparable levels of maturation
in pDCs compared to Influenza or imiquimod. PDC were stained
for activation markers, using similar co-culture conditions as
described above. In Influenza stimulated samples, we observed
early (at 3 hours) upregulation of CD83, followed by dual
expression of CD83 and CD86, and subsequently downregulation
of CD83 but persistent CD86 expression (24 hours) (Fig. 5). In
HIV stimulated cells, there was markedly delayed expression of
CD83 and CD83/86 co-expression (Fig. 5). Although an extended
time course was not performed, it appears that HIV induced
a similar sequence of CD83 followed by CD86 up-regulation, but
with delayed kinetics. Thus, compared to imiquimod or other
RNA viruses such as influenza, HIV delays pDC maturation.
HIV Induces Elevated SYK Phosphorylation
BDCA-2 has been identified as an inhibitory receptor on pDCs:
ligation of BDCA-2 results in both diminished IFN-a responses as
well as ineffective maturation [32,33,34] and HIV gp120 has
previously been shown to ligate BDCA-2 [35]. Thus, we sought to
determine whether the suboptimal IFN-a production, diminished
cytokine production and delayed maturation could be a result of
signaling through BDCA-2. BDCA-2 signaling utilizes a BCR-like
signaling cascade involving SYK phosphorylation [36]. Using
antibody specific to phosphorylated SYK (Y352), we demonstrate
upregulation of intracellular phosphorylated SYK in pDCs within
15 minutes of exposure to HIVBAL virus (Fig. 6A). This
upregulation is sustained up to 90 minutes, at levels comparable
to pDCs stimulated with cross-linking anti-BDCA-2 antibody. In
contrast, Influenza stimulated cells did not demonstrate any
appreciable increases in intracellular SYK levels. Previous reports
indicate that SYK in pDCs is phosphorylated at multiple tyrosine
sites, including Y352, Y525/526, and Y348. Using antibodies
specific for phosphorylated SYK, we show that HIV induces
phosphorylation of SYK at both tyrosine sites. In addition,
monomeric gp120 treatment of pDC also induced SYK
phosphorylation (Fig. 6C). Thus, HIV is capable of inducing
SYK phosphorylation in pDCs, in part through gp120, indicating
activation of the inhibitory BDCA-2 signaling cascade. To further
demonstrate that BDCA2 signaling inhibits virus or TLR ligand
induced IFN-a production, pDC were co-cultured with viruses or
imiquimod in the presence of BDCA2 stimulating antibody or
isotype control. All BDCA-2 stimulated conditions were associated
with reduced IFN-a (Fig. 6D).
Discussion
In this report, we provide evidence that HIV stimulation of
pDCs induces sub-optimal responses compared to other viruses
and stimuli in multiple areas, including cytokine profile, IFN-
a production, and maturation kinetics. Furthermore, we provide
data supporting a mechanistic explanation of these suboptimal
responses, involving the inhibitory BDCA-2 signaling pathway.
The uniquely rapid and robust ability of pDCs to produce IFN–
a implicates these cells as key players during early critical events of
virus exposure. Although pDCs are rapidly recruited to the vaginal
mucosa following intravaginal exposure to SIV, subsequent viral
dissemination occurs [20], indicating potential defects in the pDC
response to HIV/SIV. Although in vitro studies have repeatedly
demonstrated the ability of HIV to induce IFN-a in pDCs, most of
these studies have utilized high doses of HIV in the range of 300–
900 ng/ml of p24 antigen [19,21,22]. These doses are likely
unrepresentative of levels of virus that are sexually transmitted, as
there is evidence that HIV infection is established primarily by
a small founding population of virus [20,37]. We attempted to use
amounts of HIV in our experiments that estimated levels found
during transmission in vivo. The amounts of virus used in our
studies ranged from 10
8 to 10
10 RNA copies of HIV/experiment,
which are similar in quantities used in sexual transmission studies
Figure 4. Cytokine expression profiles following stimulation.
Isolated pDCs from HIV negative donors were rested overnight, and
treated with a panel of stimuli as described in the materials and
methods. Cytokines were quantified in culture supernatants by
cytometric bead array. Mean 6 SEM concentrations of (A) MIP-1b,( B)
IP-10, and (C) TNF-a from 5 donors are shown at various time points
following stimulation by HIVBAL, (red), HIV NL43 (orange), Influenza
(yellow), HSV (green), Imiquimod (light blue), Sendai virus (dark blue),
and medium control (white). Neither IL-10 nor IL-12p70 was detected in
any of the supernatant samples.
doi:10.1371/journal.pone.0037052.g004
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37052of SIV infection of rhesus macaques [38]. Although it is difficult to
accurately determine the amount of HIV required to directly
transmit virus at the genital mucosa, the amounts used in our
experiments were also within the range described in blood during
acute HIV infection [39], and somewhat higher than observed in
semen associated with a high rates of transmission [40,41].
In order to provide a more reliable platform for comparison, we
examined pDC responses to similar doses of different viruses.
Through this method, we demonstrate that HIV is relatively
suboptimal at IFN-a induction, with responses that are both
delayed, and less robust. PDCs stimulated by Influenza produce
IFN-a within 4 hours of exposure, emphasizing these cells as early
mediators of immune responses. HIV has rapid replication kinetics
with a half life of ,6 hours; it is therefore conceivable that a 12
hour delay in the pDC response is sufficient to allow several
rounds of replication to occur before IFN-a is able to exert its
antiviral effects.
Similar defects in both maturation and cytokine production
were observed when comparing HIV stimulated pDCs to pDCs
stimulated by other viruses. Delays in the upregulation of CD83
and CD86 were seen, compared to Influenza, which is a robust
activator of pDCs. CD83 and CD86 are typical markers used to
gauge dendritic cell maturation as well as antigen presentation and
T-cell activation capacity [15,30,42]. Despite this, the role of these
markers in pDC mediated T-cell activation is still poorly defined.
Remarkably, in both HIV and Influenza stimulated pDCs, the
upregulation of CD83 and CD86 occurred with distinct kinetics;
CD83 upregulation occurred early following stimulation and
eventually declined, whereas CD86 upregulation occurred later
following stimulation. The implications of these observations on
recruitment and activation of T-cells at the sites of HIV exposure
remains to be explored. In addition to maturation, we examined
whether or not HIV induced comparable cytokine profiles
compared to other stimuli. With the exception of IP-10, the levels
of cytokine and chemokines induced by HIV were less robust
compared to other viruses. Interestingly, IP-10 is involved in the
recruitment of macrophages and T-cells [43] and has also been
implicated in stimulating HIV viral replication [44].
Our finding that HIV tends to downregulate pDC production of
IFN-a and cytokine in comparison to other viruses, questions the
paradigm that immune activation by pDC is a driving force of
viral replication in infected individuals [45]. Previous studies have
used large doses of HIV, 20 to 100 fold more than used in our
experiments to study interactions of HIV with pDC [46]. It is
possible that the quantities of HIV used in our studies may more
accurately reflect how pDC are interacting with HIV in vivo.
Clearly, further work studying pDC activation ex vivo from recently
infected individuals may help to delineate the role of pDC and
immune activation during HIV infection.
Our results are consistent with recent studies by Gondois-Rey et
al comparing pDC responsiveness to HCV, HIV, HSV and
Influenza, in which viral treatments were normalized by genome
copy number [47]. Remarkably, compared to Influenza or HSV,
pDCs demonstrated diminished IFN-a responses to HIV as well as
HCV, another virus that establishes chronic infection. Together
with our results, these data suggests that pDC responses to HIV
are in general less robust and less rapid compared to other viruses
and stimuli. Recently, O’Brien et. al. demonstrated, that pDC pre-
stimulated with HIV can continue to produce IFN-a and cytokines
upon restimulation with HIV or other viruses and lose the capacity
to become refractory compared to pre-stimulation with TLR
agonists [48]. This is consistent with the notion that HIV may sub-
optimally stimulate pDC upon initial exposure thus, making them
less refractory to subsequent stimuli, a phenomenon that has been
demonstrated with T cell stimulation [49].
Variations in pDC responsiveness can be accounted for by
intrinsic differences in viral genomes. For instance, differences in
the number of stimulatory sequences present in virus genomes
may affect for the potency of pDC responses. Recently, specific
uridine-rich sequences in the HIV genome have been shown to
have TLR7 stimulatory capacity [50]; similar studies examining
Influenza, HSV and other RNA viruses remain to be performed.
Furthermore, the length of viral genome may dictate the amount
of stimulatory material present. Influenza, for instance, has 8 single
stranded RNA segments that in total are 13588 nucleotides in
length [51]. HIV virions on the other hand each contain two
copies of single stranded RNA that are around 9750 nucleotides in
length each [52]. However, our experiments used 3 logs more
HIV nucleotides than influenza raising the possibility that HIV is
obstructing pDCs from mounting an effective response.
In addition to the above, we hypothesized that HIV may be
involved in the active inhibition of the pDC response through
ligation of BDCA-2. Ligation and cross-linking of the BDCA-2
receptor on pDCs inhibits both maturation and interferon
production [36,53] Furthermore, gp120 from HIV is capable of
binding to BDCA-2 and abrogating pDC responsiveness [35].
BDCA-2 signaling utilizes a B-cell receptor signalosome, involving
factors such as SYK [36,53]. Upon measuring SYK phosphory-
lation, we demonstrate phosphorylation of SYK at multiple
tyrosine sites following exposure to HIV and gp120, suggesting
that HIV may actively hijack the BDCA-2 signaling pathway in
order to subvert the normal rapid pDC response. Recently,
hepatitis B surface antigen (HbsAg) has also been shown to ligate
BDCA-2 [54], suggesting that inhibition of pDC responses may be
an important factor in a variety of viral infections. However, the
mechanisms downstream of BDCA-2 ligation that affect pDC
signaling are still unknown. Further studies examining the
phosphorylation of molecules involved in pDC activation in




Informed consent was obtained in accordance with the guide-
lines for conduction of clinical research at the University of
Toronto and Maple Leaf Clinic institutional ethics boards. Written
Informed Consent and study approval was provided by the
institutional research ethics boards of the University of Toronto,
Canada and of St. Michael’s Hospital, Toronto, Canada. Human
samples were obtained through blood draw or leukopheresis of
HIV negative donors.
Figure 5. Kinetics of CD83 and CD86 upregulation. Isolated pDCs from HIV negative donors were treated with Influenza (M.O.I=0.5),
imiquimod (20 mg/ml), or HIV (M.O.I=0.5) for various time points and harvested for analysis by flow cytometry for surface expression of CD83 and
CD86. (A) Representative contour plots of CD83 and CD86 upregulation at various time points post stimulation by Influenza, showing distinct kinetics
of CD83 and CD86 upregulation. (B) Percentage of pDCs that are CD83 single positive (SP, Blue bars), CD83/CD86 double positive (DP, Purple bars),
CD86SP (Red bars), and double negative for both markers (DN, gray bars) at time points post stimulation with Influenza, imiquimod or HIVBAL. (C)
Percentages of pDCs that are CD83
+ or CD86
+ at time points post stimulation. Data shown are representative of at least 3 different donors stimulated
and stained in duplicate.
doi:10.1371/journal.pone.0037052.g005
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37052Figure 6. HIV induces upregulation of pSYK. (A) Purified pDCs were treated with Influenza and HIVBAL for various time points. Positive control
with anti-BDCA-2 antibody (1:100) treated for 30 minutes is shown. Cells were harvested, permeabalized and stained for pSYK (Y352) as described in
the materials and methods. Shown are representative histograms from 3 independent experiments. (B) PDCs were stimulated with HIVBAL, HIV NL43,
Influenza, or medium alone for 30 minutes and percentages of pDCs staining positive for pSYK (Y352) and pSYK (Y525/526) were evaluated by flow
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PBMCs were isolated by a Ficoll-Paque Plus gradient (Amer-
sham Biosciences, Piscataway, NJ). PBMCs were plated at
1610
6 cells/well with 200ul of R10 media (RPMI 1640 medium
with 10% FBS, L-glutamine, 100 units/ml Penicillin G and
100 mg/ml of Streptomycin (Gibco-Invitrogen, Carlsbad, CA)
supplemented with 20 ng/ml of human recombinant IL-3 (R&D
Systems, Minneapolis, MN) in 96-well flat-bottom plates.
Cells were stimulated with Influenza A/PR/8/34 (Charles
River Laboratories, Wilmington, MA), or HIVBAL for 8 hours at
37uC and 5% CO2. Subsequently, cells were harvested and pDCs
were identified by staining for surface expression of BDCA-2
(BDCA-2-FITC, Miltenyi Biotec, Auburn, CA) and the absence of
CD14 (CD14-APC, BD Pharmingen, San Diego, CA). Cells were
also stained for the expression of CD83 (CD83-PerCP, Biolegend,
San Diego, CA) and CD86 (CD86-APC, Biolegend,). Samples
were analyzed on a FACSCalibur
TM flow cytometer using
CellQuest software (BD Biosciences, San Diego, CA) and analyzed
by Flow Jo Software (Treestar, Ashland, Oregan). HIV viral stocks
were generated and titred in HIV negative PBMCs as previously
described [55].
IFN-a ICS
PBMCs were stimulated as above, with the addition of
GolgiPlug
TM (BD Biosciences) at 7 hours prior to the end of
incubation to block golgi transport. Following incubation, cells
were harvested and stained for surface expression of BDCA-2 and
CD123. Cells were then permeabalized with Cytofix/Cyto-
perm
TM (BD Biosciences) and stained for intracellular IFN-
a (IFN–a-PE, Chromaprobe, Maryland Heights, MO) in Perm/
Wash Buffer
TM (BD Biosciences) as per manufacturer’s instruc-
tions. Samples were analyzed by flow cytometry as described
above.
Isolation of pDCs
Purified pDCs were enriched by negative depletion using
Miltenyi pDC Isolation Kit (Miltenyi Biotec) and LD columns
(Miltenyi Biotec) following manufacturer’s instructions. Purity of
the enriched cell population was evaluated by staining for surface
expression of BDCA-2 (BDCA-2-FITC, Miltenyi Biotec) and
CD123 (CD123-PE, Miltenyi Biotec). Purity ranged from 80–
95%, and yields ranged from 0.06%-0.23%.
IFN-a ELISA
Isolated pDCs were plated at 2–3610
4 cells/well with 100 ul of
R10 (Gibco-Invitrogen) +20 ng/ml of IL-3 (R&D) in 96 well flat-
bottom plates, and left overnight at 37uC, 5% CO2. PDCs were
stimulated the next day with HIVBAL (M.O.I=0.5), HIVNL43
(M.O.I=0.5), Influenza (M.O.I=0.5) or media alone for 8 hours.
Supernatants were harvested, transferred to V-bottom 96 well
plates, centrifuged to remove cell debris, and stored at 220uC.
IFN-a levels were quantified by a pan-specific IFN-a ELISA
(Mabtech, Nacka Strand, Sweden) according to manufacturer’s
instructions.
HSV-2 Virus Generation
Vero cells (African green monkey kidney epithelial cells)
generously provided by Scott Gray-Owen (University of Toronto,
Toronto, ON) were cultured at 37uC in DMEM supplemented
with 5% BS and grown on T25 flasks to 80% confluency. Cells
were infected at an M.O.I of 0.1 with stock HSV-2, a gift from J.
Newton (McMaster University, Hamilton ON) for 24–48 hours, or
until detachment from plate surface was observed. Cells were
harvested and sonicated with a probe sonicator, and virus was
harvested from cell debris following centrifugation. Viral titer was
determined by performing serial dilutions of virus stock on plated
Vero target cells at 80% confluency in 6 well plates. Following 48
hours of infection, media was aspirated and cells were stained with
500 ul of crystal violet stain and plaques were counted.
PDC Stimulation
The following viruses were used for pDC stimulation: Influenza
A/PR/8/34 (H1N1, lot #4XAPR060202), Sendai Virus, Cantell
strain (ATCC VR-907 Para-influenza 1, in amnioallantoic fluid)
(lot #7Y050401B), both were obtained from Charles River
Laboratories (Wilmington, MA). HIV isolates were obtained from
the NIH AIDS Reagent Program. HSV-2 viruses were prepared
as above. ID50s were obtained for the following viruses after
culture in PHA stimulated PBMC blasts for HIV isolates, in chick
egg cultures for influenza and sendai, and Vero cell cultures for
HSV. Thus, MOI were determined based on their respective
ID50s.
Purified pDCs were plated at 2610
4 cells per well in R10
(Gibco-Invitrogen) +20 ng/ml IL-3 (R&D) and rested at 37uC, 5%
CO2 overnight. The next day, cells were stimulated with the
following panel: a) 18 HA/ml Sendai Virus Cantell strain (Charles
River), b) HSV-2 (M.O.I=0.5), c) HIVBAL (M.O.I=0.5) d)
Influenza (M.O.I=0.5, Charles River), e) HIVNL43 (M.O.I=0.5)
and f) 20 mg/ml of imiquimod (Invivogen, San Diego, CA) [56].
Supernatants were harvested from individual wells into V-bottom
96 well plates at 4, 8, 12, 24, and 48 hours post stimulation, and
spun down at 1500 rpm for 10 minutes to remove cell debris.
Supernatants were stored at -20uC until analysis.
Viral RNA Quantification
Quantification of HIV RNA copy numbers was determined
using Cobas Ampliprep/Cobas Taqman HIV Test, version 2.0
(Roche Diagnostics, Pleasanton, CA). Determination of influenza
RNA copies was performed using a TaqMan qPCR system against
Flu Matrix 2 gene as previously described [57] and performed on
an ABI Prism 7900HT Sequence detection System (Foster City,
CA).
Quantification of Cytokines by Cytometric Bead Array
Supernatants were thawed at room temperature, diluted
appropriately, and the presence of a panel of cytokines was
measured by BD Cytometric Bead Array Flex sets (BD
Biosciences) according to the manufacturer’s instructions. Briefly,
supernatants were diluted with Assay Diluent (BD Human Soluble
Protein Master Buffer Kit), and incubated for one hour with
a mixture of beads specific for detecting levels of IL-6 (BD,
cytometry (n=3). In (C) gp120 induces pSyk signaling in pDCs. Purified pDCs were stimulated for 90 minutes in the presence of 1 mg/ml monomeric
gp120, AN1, (blue); 20 mg/ml imiquimod, (red); or the absence of stimulation (black). Cells were harvested and stained for pSyk (pY348) and analyzed
by flow cytometry. Shown is a representative flow cytometric plot of two experiments. (D) pDCs were stimulated with 0.5 M.O.I. of HIVBAL, HIV NL43,
Influenza, and imiquimod, or medium alone for 24 hours in the presence or absence of anti-BDCA2 antibody or an IgG1 isotype control and IFN-a was
measured by ELISA (n=2, performed with two independent replicates, *p,0.001, **p,0.00005). BDCA2 treated pDC completely abrogated IFN-
a production in the presence of HIV (bars not seen).
doi:10.1371/journal.pone.0037052.g006
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B7), IL-12p70 (BD, coordinate E5), TNF-a (BD, coordinate C4),
IFN-a (BD, coordinate B8), MIP-1b (BD, coordinate B9) and IP-
10 (BD, coordinate B5). Recombinant human protein standards of
each cytokine were run along with each sample set. After initial
incubation, a master mix containing PE-conjugated detection
antibodies was added to the beads and the mixture was further
incubated for 2 hours. The beads were then washed in Wash
Buffer (BD Biosciences) and analyzed by flow cytometry. Standard
curves were generated using FCAP Array software (Soft Flow,
Burnsville, MN) and sample mean fluorescence was measured by
Flow Jo Software (Treestar, Inc.).
Phosflow Assay
Phosflow was performed to measure the phosphorylation state
of intracellular SYK following stimulation. Purified pDCs were
plated at 2610
4 cells per well in R10 (Gibco-Invitrogen) +20 ng/
ml IL-3 (R&D), and stimulated with Influenza (M.O.I=0.5,
Charles River), HIVBAL (M.O.I=0.5), 20 mg/ml of imiquimod
(Invivogen) or anti-BDCA-2 mAb (Miltenyi Biotec) for 15, 30, 60,
and 90 minutes. Cells were then fixed in prewarmed BD Phosflow
Fix Buffer I (BD Biosciences) and incubated at 37uC for 10
minutes then permeabalized with BD Phosflow Perm buffer III
(BD Biosciences). Cells were then washed with PBS +2% FBS, and
intracellular phosphorylated SYK was stained with the following
antibodies: p-SYK (Y348) (p-SYK-PE, BD Biosciences), p-SYK
(Y525/526 and Y352) (Cell Signaling Technologies, Beverly MA)
followed by PE-anti-Rabbit IgG (Ebioscience, San Diego, CA).
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